SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology

HOUSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/SpinalCyte?src=hash" target="_blank"gt;#SpinalCytelt;/agt;–SpinalCyte, LLC, a clinical stage regenerative medicine company focused
on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs),
today announced a new comprehensive resource to raise awareness of the
potential benefits of fibroblasts and provide a growing knowledge base
for this promising regenerative medicine technology.

The company’s website, www.spinalcyte.com,
now features company and independent research studies demonstrating the
potential of this new cell source for disc repair and other disease
pathways.

“Fibroblasts hold significant advantages over mesenchymal stem cells,”
said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author
of an analysis comparing the two cell sources published in the Journal
of Translational Medicine. “As we and other leading researchers
continue to advance the science in this field, our website will be the
best place to find the latest and most up-to-date information on the
healing power of fibroblasts.”

SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and
international patents issued and 85+ patents pending focused on the
clinical utility of fibroblasts.

“Fibroblasts are the regenerative cell source of the future,” said Pete
O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our
intellectual property demonstrates the versatility of this technology
and positions us as the unquestioned frontrunner in this emerging
sector. We look forward to presenting new research from around the globe
highlighting the promise of fibroblasts.”

About Degenerative Disc Disease

Degenerative disc disease (DDD) is a condition in which a patient’s
spinal disc breaks down and can begin to collapse. It is estimated that
85% of people over the age of 50 have evidence of disc degeneration and
over 1.3 million procedures a year are performed to treat the disease.
The most common treatments for patients with DDD are either discectomy
or spinal fusion. Discectomy is the partial or full removal of the
degenerated disc to decompress and relieve the nervous system but can
cause long term spinal pain. In a spinal fusion procedure, the entire
disc is removed and the two adjacent vertebrae are fused together. It
often increases strain on the adjacent discs and surrounding tissues
leading to further degeneration.

About CybroCell

CybroCell is the first off-the-shelf allogenic human dermal fibroblast
(HDF) product for the treatment of degenerative disc disease.
SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal
fibroblasts in the treatment of DDD demonstrated after 18 months,
patients injected with CybroCell had sustained improvement in pain
relief and increased back mobility.

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine
company developing an innovative solution for spinal disc replacement
using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and
international issued patents and has filed for an additional 85+ patents
pending and issued across a variety of clinical pathways, including disc
degeneration, cancer, diabetes, liver failure and heart failure.
SpinalCyte represents the next generation of medical advancement in cell
therapy. Visit www.spinalcyte.com.

Contacts

David Schull or Ned Berkowitz
Russo Partners LLC
858-717-2310
646-942-5629
[email protected]
[email protected]

Clinical Contact:
[email protected]